Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Low Dose Ketamine Infusion for the Treatment of Resistant Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04283058
Recruitment Status : Withdrawn (Covid-19 disruption of team)
First Posted : February 25, 2020
Last Update Posted : May 1, 2020
Sponsor:
Collaborators:
Sarah Capalla
Ebony HIllery
Kaushik Mukherjee
Timothy Lee
Information provided by (Responsible Party):
Patti Radovich, Loma Linda University

Tracking Information
First Submitted Date February 21, 2020
First Posted Date February 25, 2020
Last Update Posted Date May 1, 2020
Estimated Study Start Date June 29, 2020
Estimated Primary Completion Date December 29, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: April 29, 2020)
Change in Participants Depressive Symptoms [ Time Frame: within 24 hours ]
The number of participants treated with Ketamine will have a change in their depressive symptoms using The Quick Inventory of Depressive Symptomatology (QIDS SR-16) completed pre and 24 hours post infusion by Psychiatry MD, vital signs pre, every 15 minutes during infusion and within 5 minutes of completion of infusion and every 15 minutes after until patient is has a PARS of 8 or greater or is back to baseline.
Original Primary Outcome Measures
 (submitted: February 21, 2020)
Depression [ Time Frame: within 24 hours ]
Decrease of depression symptoms
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Low Dose Ketamine Infusion for the Treatment of Resistant Depression
Official Title Low Dose Ketamine Infusion for the Treatment of Resistant Depression
Brief Summary The purpose of this investigator-initiated observational study is to examine how low Ketamine infusion treatments impact antidepressant and anti-suicidal effects for refractory and non-refractory depression.
Detailed Description

This is a descriptive research study that will be collecting prospective outcome data in patients who have been examined Psychiatry and the Intensive Care Unit attending. This study will follow the patients examined and screened by both Psychiatry and the Intensive Care Unit attending physician with orders for the use of ketamine bolus. This study will be examining outcomes of the treatment and will be conducted within adult patients The electronic health records will be reviewed for follow up.

The Primary Objective is to examine the use of Ketamine and the patient outcomes following treatment in individuals with treatment resistant depression. The subjects with treatment resistant depression will be identified by Psychiatric Consult using the Quick Inventory of Depressive Symptomatology evaluation tool, have treatment resistant depression, no history of psychosis, no active substance use, admitted to medical floor and confirmed acceptance to a local Behavioral Medical Center.

Procedures involved (Research Interventions):

Psychiatric consult that includes:

  1. A full diagnostic psychiatric interview will be conducted to determine referral appropriateness and discuss other options
  2. Review of systems and medical history completed
  3. Discussion of treatment alternatives
  4. Discussion of off-label use of Ketamine for treatment resistant depression
  5. Any necessary labs or additional consults will be suggested at this time. .
  6. Review the need to remain NPO for 8 hours prior to treatment and not to take benzodiazepines (i.e., Ativan, Valium, Xanax, Klonopin), alcohol or narcotics (i.e., oxycodone, oxycontin, dilaudid, etc.) within 8 hours of the treatment with the patient.
  7. Vitals Assessed on Evaluation - Cardiovascular parameters

    1. Resting systolic BP between 90 and 150
    2. Resting diastolic between 50 and 90 on exam.
    3. If BP is above these parameters, will recommend hypertension be addressed with patient's primary team prior to treatment.

      Quick Inventory of Depressive Symptomology Evaluation (see attached evaluation tool)

      Infusion of Ketamine per physician orders:

    4. Ketamine 0.5mg/kg* dose IV in 50 mL NS will be infused at a set non-titratable rate over 40 minutes or Ketamine 1mg/kg* dose IV in 50 mL NS will be infused at a set rate non-titratable over 90 minutes. The dose that the subject will receive will be determined by the Intensive Care Unit Attending based on patient symptoms. Ketamine administered at these doses may result in the following adverse reactions such as excessive sedation or drowsiness, or unpleasant hallucinations, agitation or dysphoric reaction, nausea or increased oral secretions.

Data collection procedures: The following items will be extracted from the patient's electronic health record: The Quick Inventory of Depressive Symptomatology (QIDS SR-16) completed pre and 24 hours post infusion by Psychiatry MD, vital signs pre, every 15 minutes during infusion and within 5 minutes of completion of infusion and every 15 minutes after until patient is has a PARS of 8 or greater or is back to baseline.

Each subject will be given a unique identification number that will be used on all data collection forms post procedure (infusion). The data will be de- identified after data analysis. The key code will be stored in a separate location from the data stored in secure drive on hospital computer.

Individual subjects may benefit by treatment of their depression. Societal benefits will be an increase in provider knowledge of the effect of this treatment for resistant depression and the ability to quickly treat depression in an acute care setting.

References

  1. Kishimoto, T., et al., Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychological Medicine, 2016. 46(7): p. 1459-1472.
  2. Fond, G., et al., Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl), 2014. 231(18): p. 3663-76.
  3. Han, Y., et al., Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies. Neuropsychiatr Dis Treat, 2016. 12: p. 2859-2867.
  4. Sanacora, G., et al., A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry, 2017. 74(4): p. 399-405.
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population treatment resistant depression
Condition Depression
Intervention Drug: Ketamine
d. Ketamine 0.5mg/kg* dose IV in 50 mL NS will be infused at a set non-titratable rate over 40 minutes or Ketamine 1mg/kg* dose IV in 50 mL NS will be infused at a set rate non-titratable over 90 minutes. The dose that the subject will receive will be determined by the Intensive Care Unit Attending based on patient symptoms. Ketamine administered at these doses may result in the following adverse reactions such as excessive sedation or drowsiness, or unpleasant hallucinations, agitation or dysphoric reaction, nausea or increased oral secretions.
Other Names:
  • Ketalar
  • Dissaciative anesthetic
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Withdrawn
Actual Enrollment
 (submitted: April 29, 2020)
0
Original Estimated Enrollment
 (submitted: February 21, 2020)
50
Estimated Study Completion Date December 29, 2020
Estimated Primary Completion Date December 29, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • treatment resistant depression

Exclusion Criteria:

  • Patients excluded by SICU/ER attending for treatment based on the following relative contraindications:

    1. Coronary artery disease
    2. Increased intraocular pressure (glaucoma)
    3. Increased intracranial pressure
    4. Uncontrolled hypertension
    5. Kidney dysfunction
    6. Liver dysfunction
    7. Cardiac decompensation
    8. Psychotic disorders (needs further evaluation)
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 89 Years   (Adult, Older Adult)
Accepts Healthy Volunteers Yes
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT04283058
Other Study ID Numbers LomaLindaU
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: No
Responsible Party Patti Radovich, Loma Linda University
Study Sponsor Loma Linda University
Collaborators
  • Sarah Capalla
  • Ebony HIllery
  • Kaushik Mukherjee
  • Timothy Lee
Investigators
Principal Investigator: Patricia Radovich, PhD Loma Linda University Medical Center
PRS Account Loma Linda University
Verification Date April 2020